S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

Poseida Therapeutics (PSTX) Earnings Date, Estimates & Call Transcripts

$2.04
+0.01 (+0.49%)
(As of 04/17/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Mar. 7)
-$0.27 Beat By $0.09
Consensus EPS
(Mar. 7)
-$0.36
Skip Charts & View Estimated and Actual Earnings Data

PSTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PSTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Poseida Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.51)($0.45)($0.48)
Q2 20242($0.53)($0.45)($0.49)
Q3 20242($0.55)($0.45)($0.50)
Q4 20242($0.57)($0.46)($0.52)
FY 20248($2.16)($1.81)($1.99)

PSTX Earnings Date and Information

Poseida Therapeutics last announced its earnings data on March 7th, 2024. The reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.09. The company had revenue of $25 million for the quarter, compared to analyst estimates of $12.50 million. Poseida Therapeutics has generated ($1.39) earnings per share over the last year (($1.39) diluted earnings per share). Earnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.77) to ($1.92) per share. Poseida Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Poseida Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)
------- 
3/7/2024Q4 2023($0.36)($0.27)+$0.09($0.27)$12.50 million$25.00 million
11/9/2023Q3 2023($0.29)($0.35)($0.06)($0.35)$11.50 million$9.35 million
8/8/2023Q2 2023($0.53)($0.32)+$0.21($0.32)$10.00 million$20.01 million
5/9/2023Q1 2023($0.40)($0.45)($0.05)($0.45)$10.00 million$10.34 million
3/9/2023Q4 2022$0.47($0.39)($0.86)($0.39)$35.00 million$10.05 million
11/10/2022Q3 2022($0.68)$0.92+$1.60$0.92$2.00 million$116.31 million
8/11/2022Q2 2022($0.84)($0.69)+$0.15($0.69)$2.00 million$2.70 million
5/12/2022Q1 2022($0.58)($0.93)($0.35)($0.93)$2.50 million$1.44 million
3/10/2022Q4 2021($0.34)$0.02+$0.36$0.02$23.75 million$31.24 million
11/9/2021Q3 2021($0.74)($0.68)+$0.06($0.68)--
8/12/2021Q2 2021($0.63)($0.74)($0.11)($0.74)--
5/11/2021Q1 2021($0.64)($0.62)+$0.02($0.62)--

Poseida Therapeutics Earnings - Frequently Asked Questions

When is Poseida Therapeutics's earnings date?

Poseida Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on PSTX's earnings history.

Did Poseida Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Poseida Therapeutics (NASDAQ:PSTX) reported ($0.27) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.36) by $0.09. Learn more on analysts' earnings estimate vs. PSTX's actual earnings.

How much revenue does Poseida Therapeutics generate each year?

Poseida Therapeutics (NASDAQ:PSTX) has a recorded annual revenue of $64.70 million.

How much profit does Poseida Therapeutics generate each year?

Poseida Therapeutics (NASDAQ:PSTX) has a recorded net income of -$123.43 million. PSTX has generated -$1.39 earnings per share over the last four quarters.

What is Poseida Therapeutics's EPS forecast for next year?

Poseida Therapeutics's earnings are expected to decrease from ($1.77) per share to ($1.92) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:PSTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners